The World Bank/Rockefeller Initiative, as above.

Through its Country Assistance Strategy, the Bank can motivate attention at the country level to catalyze greater activity in areas it sees as high priority. The Bank has discussed with the Department of State the possibility of designating infectious diseases as one of those areas. The two institutions are also discussing the potential of the Bank's new policy flexibility and support for developing products for meningitis and malaria.

The Bank also co-sponsors the International AIDS Vaccine Initiative (IAVI), a fulcrum for multisectoral collaboration on a specific technology for a specific disease.

No data.

• The Bank is seeking commitments from industrial firms to take a lead in selected initiatives. At such time as a given industry expresses genuine interest, the Bank will embark on a preliminary design stage focused on two to three products to which value can be added, and/or provide support for products approaching testing in particular markets.
• The main issues emerging from the Bank's pharmaceutical industry survey were:
• • Lack of adequate information on research under way in universities, research councils, and biotechnology companies worldwide; for example, on receptors, enzymes, and compounds industry could screen to generate more product leads.
  • The need to reduce costs and duration of clinical trials without compromising safety and efficacy.
  • The need to increase market potential of products primarily for diseases in developing countries.